< 5 min
Onset objective via intranasal CNS targeting
Kinetic Precision in
Neurotherapeutics
A first-in-class NET positive allosteric modulation program targeting the kinetics of synaptic clearance, rather than the volume of neurotransmitter presence.
Current treatment paradigms primarily manipulate concentration. Our framework targets processing efficiency within endogenous clearance pathways.
kcat
Catalytic turnover modulation over receptor blockade
Pulsatile
State-management deployment, not chronic suppression
Three Program Pillars
A coordinated translational architecture for delivery, safety, and responder precision.
Direct CNS Targeting
Intranasal perineural transport through olfactory and trigeminal pathways is designed to align onset timing with acute phasic demand.
Retrometabolic Safety
Soft-drug architecture supports bounded central activity with peripheral inactivation logic to reduce sustained off-target exposure risk.
Biomarker Stratification
Responder identification is anchored to kinetic mismatch signatures, including the Sensory-Autonomic Triad phenotype for cleaner cohort selection.
From chronic suppression to acute restoration.
Therapeutics designed to work with endogenous clearance machinery to constrain signal radius and dwell-time, while preserving task-relevant phasic fidelity.